5th Clinical Trials Phase I and Phase IIA Summit

Sponsors often take for granted the fact that early phase trial design and operations can make or break future studies. When hard data is severely limited and is used to predict well beyond its boundaries, the quality of that data is absolutely paramount. The data obtained from phase 1 first-in-human studies through phase two proof-of-concept and dose range finding studies are vital to effectively designing future registration studies. Early phase clinical trials should be safe experiments on humans, not small-scale phase three trials. Therefore, it is beneficial to intelligently optimize early phase clinical activity to ensure successful trial execution and regulatory approval.

The mission of the 5th Clinical Trials Phase I and Phase IIA Summit is to provide attendees with the strategies and insight necessary to ensure their early stage clinical trials are executed on time and within budget while exploring how to leverage innovative approaches to managing clinical trials for all therapeutic areas.

Prices:
EARLY BIRD PRICING – Register before Friday, September 7, 2018: USD 1895.0
STANDARD PRICING: USD 2095.0
ON SITE PRICING: USD 2195.0

Read More

View Less